Company profile: Eleusis
1.1 - Company Overview
Company description
- Provider of clinical-stage psychedelic-based therapeutics and care delivery solutions, including ELE-Psilo, an investigational IV psilocin candidate for major depressive disorder; a platform for screening, treatment, monitoring, and continuing care to enhance safety, personalization, and accessibility; clinic operations via Andala providing access to psychiatric drug therapies; and discovery programs for anti-inflammatory, neuroprotective, and other psychiatric and non-psychiatric medicines.
Products and services
- Drug Discovery and Development Programs: Eleusis develops psychedelic-based programs discovering and advancing serotonin 2A receptor agonists for psychiatric and non-psychiatric applications, including anti-inflammatory and neuroprotective medicines
- ELE-Psilo: Eleusis engineers an intravenous psilocin drug candidate for major depressive disorder, formulated for IV delivery and intended to be administered to patients with MDD
- Care Delivery Platform: Eleusis delivers a screening-to-continuing-care platform enhancing safety, enabling personalization, and ensuring accessibility of psychedelic drug therapy via integrated screening, treatment, monitoring, and continuing care workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eleusis
Virdante Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing and commercializing drugs for autoimmune and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Virdante Pharmaceuticals company profile →
Septerna
HQ: United States
Website
- Description: Provider of GPCR-focused drug discovery platforms and services, including a Native Complex Platform that reproduces receptors outside cells, enabling discovery for previously undruggable GPCRs; GPCR affinity screening; structural biology using cryo-EM; and in silico screening, plus small-molecule discovery programs targeting well-validated GPCRs across multiple therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Septerna company profile →
Stromedix
HQ: United States
Website
- Description: Provider of drugs targeting fibrosis, organ failure, and cancer, initially focused on chronic indications, with plans to expand into related settings such as acute organ failure and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stromedix company profile →
Blade Therapeutics
HQ: United States
Website
- Description: Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestat—a Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184—an IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blade Therapeutics company profile →
Taligen Therapeutics
HQ: United States
Website
- Description: Provider of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases, with lead candidates including monoclonal antibodies and recombinant fusion proteins targeting key factors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taligen Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eleusis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eleusis
2.2 - Growth funds investing in similar companies to Eleusis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eleusis
4.2 - Public trading comparable groups for Eleusis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →